South San Francisco, CA, United States of America

Coulter Pharmaceutical, Inc.


USPTO Granted Patents = 6


Forward Citations = 445

Loading Chart...
Loading Chart...

9 inventors (with patents filed for the assignee):

goldMedal Richard L Wahl (4 out of 18 patents)

silverMedal Mark S Kaminski (4 out of 6 patents)

bronzeMedal Gregory M Butchko (4 out of 6 patents)

4.  Stephan D Glenn (4 out of 13 patents)

5.  David Colcher (2 out of 2 patents)

6.  Dan Shochat (2 out of 2 patents)

7.  Michael J Buckley (2 out of 2 patents)

8.  Albert S K Chan (1 out of 1 patent)

9.  Albert S Chan (1 out of 1 patent)

10.  Sanjeev Gangwar (73 patents)

11.  Geoffrey T Yarranton (28 patents)

12.  Vincent Dubois (6 patents)

13.  Evan Lewis (2 patents)

14.  Matthew H Nieder (10 patents)

15.  André Trouet (4 patents)


6 patents:

Company Overview
Coulter Pharmaceutical, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for cancer and other serious diseases. With a focus on precision medicine, Coulter Pharma aims to bring personalized treatments to patients in need. Through cutting-edge research and strategic partnerships, the company is leading the way in delivering targeted therapies that improve outcomes and quality of life for patients.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#137 in South San Francisco, CA

#10,570 in California

#44,981 in US

South San Francisco, CA (US)
South San Francisco, CA, United States of America
Forward Citations = 445

9 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Coulter Pharmaceutical, Inc.. Retrieved from https://idiyas.com/company/coulter-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…